249 studies on GIP agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This Phase 2 trial is crucial as it explores a novel combination therapy that could significantly advance the treatment landscape for obesity and Type 2 Diabetes. If successful, combining LY3841136 with Tirzepatide co…
This study addresses a critical unmet need for patients with psoriatic arthritis who also struggle with obesity, a common comorbidity that complicates disease management and often reduces the effectiveness of existing…
Understanding the effects of GLP-1 agonist discontinuation is crucial for informing patient care and developing strategies to manage potential rebound effects and improve long-term outcomes. Many patients may need to …
Tirzepatide is already a highly effective treatment for Type II Diabetes and obesity, known for its significant glycemic control and weight loss benefits. The key implication of this study is that if Tirzepatide can d…
Tirzepatide has already demonstrated significant efficacy, and exploring higher or alternative dosing strategies could further optimize patient outcomes by potentially enhancing glycemic control and weight loss. This …
The successful completion of this Phase 3 trial is a significant milestone, as Tirzepatide (a dual GIP and GLP-1 receptor agonist) has already demonstrated robust efficacy in adults with Type 2 Diabetes and obesity. I…
This Phase 3b study represents a significant step towards developing more holistic treatment strategies for complex conditions. If successful, combining Mirikizumab and Tirzepatide could offer a novel therapeutic opti…
Tirzepatide offers a powerful new treatment option for Type 2 Diabetes Mellitus, particularly for those struggling to achieve adequate glycemic control with existing therapies. The successful completion of this Phase …
The successful completion of this Phase 1/2 trial for IBI362 could significantly impact the landscape of obesity treatment, particularly for the Chinese patient population. If IBI362 demonstrates a favorable safety pr…
Understanding how renal impairment affects IBI362's pharmacokinetics is critically important for patient safety and treatment efficacy. If kidney function significantly alters drug exposure, dose adjustments will be n…
This review underscores the critical and enduring role of bariatric surgery as the most efficacious treatment for obesity, even amidst the revolutionary advancements in GLP-1 RA pharmacotherapy. Recognizing the unique…
This study is crucial for understanding Tirzepatide's performance in patient groups often excluded from or underrepresented in randomized controlled trials. If successful, it could provide valuable evidence supporting…
If successful, this study could identify a simple, accessible, and enjoyable dietary intervention to optimize the benefits of GLP-1 therapy, potentially mitigating unwanted muscle loss and enhancing overall health out…
This review is crucial because it highlights the escalating global obesity crisis and the urgent need for novel, potentially safer, and more accessible therapeutic options. By systematically exploring natural products…
Preserving lean muscle mass is critical for maintaining metabolic health, strength, and overall quality of life during significant weight loss. If successful, this intervention could become a standard recommendation f…
Successfully demonstrating the acceptability and practicality of Tirzepatide in this population is crucial. If proven feasible, this intervention could offer a vital strategy to address obesity in breast cancer surviv…
If the EXER-MED trial demonstrates that combining exercise with tirzepatide leads to significantly better outcomes than medication alone, it could redefine the standard of care for obesity management. This research ha…
The successful completion of this Phase 1 study is a significant step forward in addressing pediatric obesity, a condition with limited pharmacological interventions. Tirzepatide, a dual GLP-1 and GIP receptor agonist…
The successful completion of this Phase 1/1b study is crucial for advancing TLC-6740 as a potential novel therapeutic agent for obesity and Type 2 Diabetes, conditions that continue to pose significant public health c…
The development of ALN-2232 represents a novel approach to treating obesity, potentially offering a new mechanism of action beyond existing therapies. If successful, this RNAi therapeutic could provide an important ne…
This study holds significant promise by exploring the potential for a novel, enhanced therapeutic approach for managing complex metabolic disorders like obesity and Type 2 Diabetes. By combining a specially formulated…
This study highlights a crucial, previously under-recognized aspect of GLP-1RA therapy: its potential impact on male sexual health. The finding that GLP-1RAs may increase the risk of erectile dysfunction suggests that…
The findings from this study are crucial because they will inform the safe and effective use of AD109 in a growing population of OSA patients who are also managing their weight or diabetes with GLP-1 medications. If A…
Obesity is a major comorbidity in breast cancer patients, negatively impacting treatment efficacy and increasing recurrence risk. This study is significant because it directly addresses the potential of a powerful wei…
This pilot study is critically important because it addresses a significant clinical challenge: achieving healthy weight loss in older adults without compromising vital muscle and bone mass. If Tirzepatide can demonst…
The investigation of eloralintide, particularly in combination with tirzepatide, represents a significant step in developing next-generation treatments for obesity. If eloralintide demonstrates a favorable safety and …
Understanding the drug effect of Tirzepatide on musculoskeletal abnormalities is critical for optimizing obesity treatment strategies. This research could provide evidence for the necessity of combining GLP-1 therapie…
This study is significant because it explores a novel therapeutic approach for two intertwined and devastating conditions: Alcohol Use Disorder and Metabolic Alcohol-associated Liver Disease. If successful, tirzepatid…
This feasibility study could provide crucial preliminary evidence for a novel and highly effective treatment strategy for obesity-related hypertension in a vulnerable young adult population. If successful, it could es…
Understanding the sex-based heterogeneity in drug response is crucial for optimizing personalized medicine approaches in CKMH. If significant differences are found, it could lead to sex-specific prescribing guidelines…
Understanding the nuanced differences in how GLP-1 receptor agonists and gastric bypass surgery affect body composition is crucial for optimizing treatment strategies for obesity. If GLP-1 RAs can achieve similar bene…
This research is highly significant as it targets a critical unmet need in Type 2 Diabetes management: patients who do not achieve adequate glycemic control even with potent GLP-1 or GLP-1/GIP receptor agonists. LY345…
This Phase 2a study is crucial because it targets a specific genetic subtype of MASLD that is often more aggressive and difficult to treat. ALN-PNP works by reducing the PNPLA3 protein, which is implicated in liver fa…
Understanding tirzepatide's effects on skeletal muscle is critically important, as preserving muscle mass during weight loss is a key challenge, especially in obesity. If tirzepatide can mitigate muscle loss or even i…
This study is crucial for understanding Tirzepatide's long-term efficacy and safety outside of highly controlled clinical trial environments. If successful, the findings could significantly inform clinical guidelines …
Understanding GIP's long-term effects on bone is critically important given the widespread use of GIP receptor (GIPR) agonists like tirzepatide for obesity and type 2 diabetes, conditions often associated with comprom…
This study holds significant promise as it could identify a new, effective pharmacological treatment for severe forms of obesity like Prader-Willi Syndrome and hypothalamic obesity, which currently have limited therap…